重庆医学2013，Vol.42Issue(9)：1025-1026,2.DOI:10.3969/j.issn.1671-8348.2013.09.026
曲妥珠单抗对HER2阳性乳腺癌患者术后辅助治疗的临床观察
Clinical observation on trastuzumab in postoperative adjuvant therapy of HER2-positive breast cancer
徐金明 1黎可 1陈轩 1童富云 1饶伟 1徐美玲1
作者信息
摘要
Abstract
Objective To investigate the effect and safety of trastuzumab in postoperative adjuvant therapy of HER2-positive breast cancer. Methods 136 patients with breast cancer radical mastectomy in this hospital from May 2006 to December 2011 were selected and randomly divided into the treatment group(68 cases) and control group(68 cases). The treatment group was given trastuzumab once every 3 weeks as the adjuvant therapy. The initial loading dose was 8 mg/kg,and the subsequent dose was 6 mg/kg by intravenous drip once every 3 weeks, with 21 d as a treatment course. The efficacy and side effects were observed in the two groups. Results The complete remission(CR),progress disease(PD) and 5-year survival rate in the treatment group had statistical difference compared with the control group(P<0. 05). Conclusion Trastuzumab is effective in postoperative treatment of HER2-positive breast cancer,which extends the survival duration with mild adverse reactions. The patients are tolerable.关键词
乳腺肿瘤/曲妥珠单抗/肿瘤辅助疗法Key words
breast neoplasm/trastuzumab/neoadjuvant therapy引用本文复制引用
徐金明,黎可,陈轩,童富云,饶伟,徐美玲..曲妥珠单抗对HER2阳性乳腺癌患者术后辅助治疗的临床观察[J].重庆医学,2013,42(9):1025-1026,2.
